Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | VCP | P55072 | 5/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MERTK | Q12866 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12057848 | 0.93 | IRAK4 (0.34) | IRAK4VCPKDM4EMERTKFLT3 | |
| SCHEMBL12057712 | 0.87 | IRAK4 (0.34) | IRAK4VCPKDM4EATMPTPN11 | |
| SCHEMBL12057987 | 0.87 | PTPN11 (0.32) | PTPN11 | |
| SCHEMBL12058185 | 0.86 | VCP (0.34) | CCNT1IRAK4VCPKDM4EATM | |
| SCHEMBL13493510 | 0.85 | IRAK4 (0.34) | CCNT1SYKIRAK4VCPKDM4E | |
| SCHEMBL12057865 | 0.85 | IRAK4 (0.34) | CCNT1SYKIRAK4VCPKDM4E | |
| SCHEMBL12038204 | 0.84 | IRAK4 (0.51) | IRAK4 | |
| SCHEMBL12038597 | 0.81 | IRAK4 (0.53) | IRAK4 | |
| SCHEMBL12057921 | 0.81 | GNRHR (0.33) | IRAK4PTPN11 | |
| SCHEMBL12058157 | 0.80 | PTPN11 (0.32) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2010022121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | CCNT1 520/4885SYK 1033/4885IRAK4 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.